RxDoctor Payments Data

Jacquelyn White, PA

Physician Assistant · Saratoga Springs, NYNPI 1811463102

Payments from drug & device makers

$2,637in general payments, 2019–2025

Across 108 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$373
  • Boston Scientific$291
  • Amgen$220
  • Edwards Lifesciences$185
  • E.r. Squibb & Sons, L.L.C.$159
  • AstraZeneca$152
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,637100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,637 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$27,573
Medicare patients
286
Services billed
477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$153,537
FarxigaDapagliflozin Propanediol34$29,519
JardianceEmpagliflozin16$21,105
EntrestoSacubitril/Valsartan19$19,120
XareltoRivaroxaban12$15,893
Repatha SureclickEvolocumab12$15,663
Praluent PenAlirocumab24$14,402
Metoprolol Succinate150$2,428
Atorvastatin Calcium118$1,425
Rosuvastatin Calcium52$763
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$687
Torsemide42$637
Amlodipine Besylate85$633
Valsartan18$521
Carvedilol46$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$153,537137 claims
AstraZenecaFarxiga$152$29,51934 claims
Boehringer IngelheimJardiance$141$21,10516 claims
NovartisEntresto$373$19,12019 claims
Johnson & JohnsonXarelto$26$15,89312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Saratoga Springs

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →